fda warning letter glp-1 october 2025 Beyond the Headlines: Letters to Compounders FDA issues 30 warning letters

We want to understand what the best alternatives might be, if they need to stop their GLP-1 medication

Side effects with current GLP-1 drugs are attributed to the triggering of alternative pathways

In addition, subjects on VYVANSE showed greater improvement as compared to placebo across key secondary outcomes with higher proportion of subjects rated improved on the CGI-I rating scale, higher proportion of subjects with 4-week binge cessation, and greater reduction in the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) total score

Clinical trials show semaglutide can cause small increases in resting heart rate, and the Wegovy SmPC lists 'heart rate increased' as an adverse reaction, though individual experiences vary considerably

Foods like these are also good sources of fiber and other nutrients

These findings help explain why two people on the same medication can have very different experiences, but they dont change how medications are prescribed today